PuriCore has announced it has had a successful first pre-IND meeting with the FDA and is on track to submit an IND application in Q1 2017 for its lead product, a topical treatment for Atopic Dermatitis. Puricore remains at an interesting juncture in its development as it transitions to a fully fledged drug development company based on leveraging its proprietary immunomodulatory technology to develop novel, topical treatments for inflammatory diseases.
09 Jun 2016
Successful pre-IND meeting
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Successful pre-IND meeting
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
09 Jun 2016 -
Author:
Chris Glasper -
Pages:
3
PuriCore has announced it has had a successful first pre-IND meeting with the FDA and is on track to submit an IND application in Q1 2017 for its lead product, a topical treatment for Atopic Dermatitis. Puricore remains at an interesting juncture in its development as it transitions to a fully fledged drug development company based on leveraging its proprietary immunomodulatory technology to develop novel, topical treatments for inflammatory diseases.